Monash’s Medicine, Nursing and Health Sciences proudly presents From the Frontline: Clinical Impacts of COVID-19.
In this free online event, we’ll explore the impact COVID-19 has had on healthcare and what the ‘new normal’ will look like post-pandemic.
Hear from our panel of experts (Prof Jane Fisher, A/Prof Julian Elliott, Prof Merlin Thomas and A/Prof Anneke van der Walt) who are leading clinician-researchers based on the frontline of our hospitals and research facilities. They’ll discuss their COVID-19 research, focus areas, and how these will impact our community.
- Date: 12 August 2020 at 6:00 pm – 7:30 pm
Categories: Public Health and Preventive Medicine; Clinical Sciences - The Alfred
Got a question?
You’ll have the opportunity to ask our experts directly by taking part in the live Q&A session.
Professor Stephen Jane
Professor Jane is Foundation Dean, Sub-Faculty of Translational Medicine and Public Health at Monash University and is Director of Research for Alfred Hospital.
Professor Jane Fisher, Finkel Professor of Global Health and Director of Global and Women’s Health, School of Public Health and Preventive Medicine, Monash University.
Jane Fisher, an academic clinical and health psychologist is Finkel Professor of Global Health in the School of Public Health and Preventive Medicine. With colleagues, she completed a recent national survey of the psychological impact of the first month of COVID-19 restrictions. She is the guest presenter on ABC Melbourne Drive each week with Rafael Epstein of Life and Other Catastrophes, a program about experiences and relationships, which has for the past three months enabled wide community discussion about the impacts of the restrictions on peoples' lives.
Associate Professor Julian Elliott - Lead for Evidence Systems at Cochrane, Senior Research Fellow at Cochrane Australia and an Infectious Diseases Physician at the Alfred Hospital
Associate Professor Julian Elliott is Executive Director of the National COVID-19 Clinical Evidence Taskforce, based at Cochrane Australia in Monash's School of Public Health and Preventive Medicine, and an infectious diseases physician at The Alfred Hospital. Faced with the challenge of a fast moving pandemic, the Taskforce brought together national clinical groups to create a unified, trusted source of health evidence to guide Australian clinicians. The foundation for this work is the 'living evidence' model developed by A/Prof Elliott and now being applied around the world in the COVID-19 response.
Associate Professor Anneke Van Der Walt - Head, MS and Neuro-ophthalmology, Alfred Health, Central Clinical School, Monash University
A/Prof Anneke van der Walt is a Neurologist specialising in the management of Multiple Sclerosis and Neuro-ophthalmology. She is leads the MSNI (Multiple Sclerosis and neuroimmunology) and Neuro ophthalmology services at Alfred Health. Her research group is based in the Department of Neuroscience, Central Clinical School, Monash University. She leads the Australian and New Zealand association of Neurologists’ collection on COVID-19 infections in people with MS or related disorders. In addition, she leads an international collaborative study on COVID-19 infections in MS using the MSBase registry. The MSBase registry hold MS outcome data on more than 70,000 people with MS in 36 countries
Professor Merlin Thomas - Clinician-scientist and Head of the Biochemistry of Diabetes Complications Laboratory, Central Clinical School, Monash University
Professor Merlin Thomas is a clinician scientist and program leader in the Department of Diabetes at Monash University. He is widely recognized as a researcher, educator and medical storyteller with over 300 publications to his name, as well as best selling books, "The Longevity List" and "Fast Living Slow Ageing". His research program is focused on understanding the mechanisms of diabetic complications and developing new opportunities for their prevention and treatment. He has been recently funded by the MRFF to translate his work with ACE2, the host receptor for SARS-CoV-2, towards the development of a new inhalable treatment for COVID-19.